Page 10 - Biological E News Today

The United States and India's Biological E. Ltd said on Monday they had finalised a financing arrangement for $50 million to expand the vaccine maker's capacity to produce COVID-19 shots.

Biological E's anti-coronavirus shot, Corbevax, is a RBD protein sub-unit vaccine and is ndergoing phase 2/3 clinical trials on adults

Biological E's anti-coronavirus shot, Corbevax, is a RBD protein sub-unit vaccine and is ndergoing phase 2/3 clinical trials on adults

He urged the companies to speed up the production of more doses in order to cover more population by December end

Representatives from seven vaccine makers -- Serum Institute of India, Bharat Biotech, Dr Reddy's Laboratories, Zydus Cadila, Biological E, Gennova Biopharma and Panacea Biotech -- will be participating in the meeting.

New Delhi: As the country achieved the milestone of vaccinating over 100 crore Indians against COVID-19 on Thursday, Indias role as the pharmacy of the world became more entrenched with the nation...

India will have a capacity of more than 30 crores by next year per month, which includes Covishield, Covaxin, ZyCoV-D and Biological E, said sources. 

The Corbevax is the third made-in-India vaccine against coronavirus, the other two indigenous vaccines are Covaxin and ZyCoV-D

Biological E to submit final data of its Covid vaccine Corbevax till November end: Report

The Corbevax is the third made-in-India vaccine against coronavirus, the other two indigenous vaccines are Covaxin and ZyCoV-D